A study of a new drug combo for large B-cell lymphoma with TP53 changes
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (glofitamab, a PD-1 antibody, and lenalidomide) for people with relapsed or refractory large B-cell lymphoma that has a TP53 change. The goal is to see if this combination works better for patients who cannot have a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have large B-cell lymphoma that has come back or not responded to treatment, and has a TP53 change (a mutation or deletion).
- You must not be eligible for a stem cell transplant (for example, due to age, organ problems, or your own choice).
- You must have at least one tumor that can be measured on a scan (lymph node at least 1.5 cm or other lesion at least 1 cm).
- You must be willing to follow study procedures, including using contraception if you could become pregnant or father a child.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (glofitamab, gemcitabine, oxaliplatin) followed by liso-cel (a CAR T-cell therapy) for people with large B-cell lymphoma who have only had one prior treatment and whose lymphoma came back. The goal is to see if this approach works better than standard treatments.
This trial tests a new combination treatment for patients with large B-cell lymphoma who did not respond well to CAR-T cell therapy (a type of immunotherapy). The study uses tumor testing to guide which drugs to use, aiming to help patients whose cancer has stopped responding or is growing again.
This trial tests combining two therapies—a CAR T-cell treatment and an antibody drug called glofitamab—for people with large B-cell lymphoma that has come back or not responded to initial treatment and has certain high-risk features.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial tests a new combination of three drugs (EZH2 inhibitor, glofitamab, and gemcitabine/oxaliplatin) for patients with diffuse large B-cell lymphoma that has stopped responding to or come back after prior treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.